GE HealthCare Q4 Revenue Rises 7% on Diagnostics and Imaging Strength
GE HealthCare Technologies delivered a robust fourth-quarter performance, with revenue climbing 7.1% to $5.7 billion. The surge was led by pharmaceutical diagnostics, which jumped over 22%, alongside steady demand for imaging and advanced visualization systems. Global markets, particularly the U.S. and EMEA regions, drove organic growth.
Net income reached $589 million, though margins faced pressure from tariff costs and product mix shifts. Adjusted EBIT stood at $950 million, reflecting ongoing operational investments. The company's backlog and software growth position it for sustained momentum through 2025.
Despite closing 1.66% lower at $78.78, GE HealthCare's results underscore its leadership in medical technology. Strategic acquisitions and strong cash Flow are expected to fuel expansion into 2026.
